CaMKIIα as a Promising Drug Target for Ischemic Grey Matter
Research output: Contribution to journal › Review › Research › peer-review
Standard
CaMKIIα as a Promising Drug Target for Ischemic Grey Matter. / Griem-Krey, Nane; Clarkson, Andrew N.; Wellendorph, Petrine.
In: Brain Sciences, Vol. 12, No. 12, 1639, 2022.Research output: Contribution to journal › Review › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - CaMKIIα as a Promising Drug Target for Ischemic Grey Matter
AU - Griem-Krey, Nane
AU - Clarkson, Andrew N.
AU - Wellendorph, Petrine
N1 - Funding Information: This work was supported by the Lundbeck Foundation (R277-2018-260). Publisher Copyright: © 2022 by the authors.
PY - 2022
Y1 - 2022
N2 - Ca2+/calmodulin-dependent protein kinase II (CaMKII) is a major mediator of Ca2+-dependent signaling pathways in various cell types throughout the body. Its neuronal isoform CaMKIIα (alpha) centrally integrates physiological but also pathological glutamate signals directly downstream of glutamate receptors and has thus emerged as a target for ischemic stroke. Previous studies provided evidence for the involvement of CaMKII activity in ischemic cell death by showing that CaMKII inhibition affords substantial neuroprotection. However, broad inhibition of this central kinase is challenging because various essential physiological processes like synaptic plasticity rely on intact CaMKII regulation. Thus, specific strategies for targeting CaMKII after ischemia are warranted which would ideally only interfere with pathological activity of CaMKII. This review highlights recent advances in the understanding of how ischemia affects CaMKII and how pathospecific pharmacological targeting of CaMKII signaling could be achieved. Specifically, we discuss direct targeting of CaMKII kinase activity with peptide inhibitors versus indirect targeting of the association (hub) domain of CaMKIIα with analogues of γ-hydroxybutyrate (GHB) as a potential way to achieve more specific pharmacological modulation of CaMKII activity after ischemia.
AB - Ca2+/calmodulin-dependent protein kinase II (CaMKII) is a major mediator of Ca2+-dependent signaling pathways in various cell types throughout the body. Its neuronal isoform CaMKIIα (alpha) centrally integrates physiological but also pathological glutamate signals directly downstream of glutamate receptors and has thus emerged as a target for ischemic stroke. Previous studies provided evidence for the involvement of CaMKII activity in ischemic cell death by showing that CaMKII inhibition affords substantial neuroprotection. However, broad inhibition of this central kinase is challenging because various essential physiological processes like synaptic plasticity rely on intact CaMKII regulation. Thus, specific strategies for targeting CaMKII after ischemia are warranted which would ideally only interfere with pathological activity of CaMKII. This review highlights recent advances in the understanding of how ischemia affects CaMKII and how pathospecific pharmacological targeting of CaMKII signaling could be achieved. Specifically, we discuss direct targeting of CaMKII kinase activity with peptide inhibitors versus indirect targeting of the association (hub) domain of CaMKIIα with analogues of γ-hydroxybutyrate (GHB) as a potential way to achieve more specific pharmacological modulation of CaMKII activity after ischemia.
KW - CaMKII
KW - excitotoxicity
KW - GHB analogues
KW - glutamate
KW - HOCPCA
KW - ischemia
KW - neuroprotection
KW - stroke
U2 - 10.3390/brainsci12121639
DO - 10.3390/brainsci12121639
M3 - Review
C2 - 36552099
AN - SCOPUS:85144643914
VL - 12
JO - Brain Sciences
JF - Brain Sciences
SN - 2076-3425
IS - 12
M1 - 1639
ER -
ID: 332687467